All News

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Despite the overall decline in medication non-adherence, adult patients with asthma are continuing to report taking less or skipping doses and refilling prescriptions later to save money.

Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Improvements were observed regardless of whether patients initiated ruxolitinib in the second or third line of treatment.

Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

Compared with placebo, patients with relapsed/refractory (R/R) follicular lymphoma (FL) who were treated with tafasitamab showed a median progression-free survival (PFS) of 22.4 months.

Ira Zackon, MD, explains where future research lies regarding the implementation of bispecific antibodies in community oncology settings.

The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.

Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.

Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.

Currently, the treatment is undergoing evaluation in a phase 2a trial.

Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.

Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.

This update follows May 2021 guidelines which recommended patients with primary biliary cholangitis (PBC) with advanced cirrhosis discontinue obeticholic acid.

The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.

Pharmacists play an essential role in educating patients about various health-related topics, including type 2 diabetes and nutrition.

Pharmacists are crucial skin care experts and should counsel patients on the importance of adjunct therapies like moisturizers and sunscreen when using certain medications.

The full results will be published in a peer-reviewed journal and presented at a medical meeting next year as the full results are evaluated.

Compared prednisolone alone, benralizumab with and without prednisolone resulted in fewer treatment failures and stronger VAS scores.

Patients with chronic graft-versus-host disease (cGVHD) were most likely to receive belumosudil in the fourth line (33.7%) setting or the fifth through seventh line (33.1%).

The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).

Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

The combination vaccine candidates will be evaluated in 2 separate phase 1/2 clinical trials.

Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.